EUVIMEDEUVIMED entdecken
Crossref

Dual Modulator of FXR and HSD17B13: Revitalizing FXR Therapies in MASH

Changhong Wei, Yun Liu, Zhiming Yan iD, Jing Han, Neng Jiang

Journal of Medicinal Chemistry · 27.03.2025 · 68 (6) · 6104-6107

DOI: 10.1021/acs.jmedchem.5c00539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 05.03.2025. Verfasst von Changhong Wei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research & Clinical Laboratory, The Fifth Affiliated Hospital of Guangxi Medical University & The First People's Hospital of Nanning, N…. Hauptthemen laut MEDLINE: Receptors, Cytoplasmic and Nuclear. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dual modulation of FXR and HSD17B13 presents a promising strategy for treating metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatohepatitis (MASH). Compound 6, a groundbreaking dual modulator of FXR and HSD17B13, validates the concept of significantly enhancing liver function, reducing inflammation and fibrosis across various MAFLD models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Cytoplasmic and NuclearHumansAnimalsEstradiol DehydrogenasesFatty Liver17-Hydroxysteroid DehydrogenasesReceptor, Farnesoid X-Activated

Substanzen

Receptors, Cytoplasmic and NuclearEstradiol Dehydrogenases17-Hydroxysteroid DehydrogenasesReceptor, Farnesoid X-ActivatedHSD17B13 protein, human

Autor:innen und Institutionen

  • Department of Research & Clinical Laboratory, The Fifth Affiliated Hospital of Guangxi Medical University & The First People's Hospital of Nanning, Nanning 530022, Guangxi, PR China.
  • Department of Pharmacy, Guangxi Medical University Cancer Hospital, Nanning 530021, Guangxi, PR China.
  • School of Chemistry & Materials Science, Jiangsu Normal University, Xuzhou 221116, Jiangsu, PR China.

ORCID-Profile: Zhiming Yan

Zitieren

APA

Wei, C., Liu, Y., Yan, Z., Han, J., & Jiang, N. (2025). Dual Modulator of FXR and HSD17B13: Revitalizing FXR Therapies in MASH. Journal of Medicinal Chemistry, 68(6), 6104-6107. https://doi.org/10.1021/acs.jmedchem.5c00539

Vancouver

Wei C, Liu Y, Yan Z, Han J, Jiang N. Dual Modulator of FXR and HSD17B13: Revitalizing FXR Therapies in MASH. Journal of Medicinal Chemistry. 2025;68(6):6104-6107. doi:10.1021/acs.jmedchem.5c00539

BibTeX
@article{Wei2025,
  author = {Wei, Changhong and Liu, Yun and Yan, Zhiming and Han, Jing and Jiang, Neng},
  title = {Dual Modulator of FXR and HSD17B13: Revitalizing FXR Therapies in MASH},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {6},
  pages = {6104--6107},
  doi = {10.1021/acs.jmedchem.5c00539}
}
Kostenlos starten →